To improve patients’ lives
Acting on this mission has propelled us to become a global biopharmaceutical leader with a focus on innovation and specialty care.
Our passion drives our commitment to patients living with difficult-to-treat diseases, and we put them first. Because patients are our priority, we help them through our expertise in oncology, neuroscience, and rare diseases.
We bring medicines to patients with the strength of nearly 6,000 employees across the globe, including innovators in our key therapeutic areas.Download our annual report
Patients are the heart of our science
That’s why we apply the rigor of data to everything we do, whether we’re working in neurology, oncology, or rare diseases—we strive to leave no patient behind. We’ve shaped our research and development pipeline with a goal of launching at least one new drug or meaningful indication every year.
Our oncology work focuses on solid tumors and some of the hardest-to-treat cancers. We power a growing portfolio of therapies aimed at improving the lives of patients with gastrointestinal and pancreatic neuroendocrine tumors, carcinoid syndrome, and pancreatic cancer.
People suffering from neurological disorders are in need of treatments, and we’ve become a global leader in creating them through the research, development, manufacturing and commercialization of neurotoxins to help treat certain types of spasticity in adults and children two years and older, and cervical dystonia in adults.
We continue to evolve and grow our research efforts in the area of rare and ultra-rare diseases. Given the limited understanding of these diseases, we are committed to addressing patient needs, from supporting diagnosis to treatment with specific investment in pituitary pathologies, growth disorders, and ultra-rare bone diseases, including fibrodysplasia ossificans progressiva, commonly known as FOP.
Clinical trials can lead to medical outcomes that help improve lives, and we thank all of our patients who make this critical research possible through their participation in trials. If you would like to learn more about enrolling in a study, visit clinicaltrials.gov.
Responsibility is our policy
Our passion for helping patients extends beyond the office walls
We endeavor to have a responsible and sustainable impact on patients, society, and the environment. We are people who aim to make a difference in our communities, both inside and outside of the workplace. We match donations from employees to support nonprofit organizations through Ipsen Gives Back, our internal matching gifts program.
Meet our leadership team
Chief Executive Officer, Ipsen North America
Vice President, Head of New Products & Innovation
Vice President, Franchise Head, Neuroscience Business Unit
Senior Vice President and North America General Counsel, Legal Affairs
Senior Vice President and Business Unit Head, Rare Disease – North America
Senior Vice President, North America, HR & Global Talent Acquisition
General Manager, Ipsen Canada
Vice President, North America Government Affairs & Public Policy
Vice President, Business Ethics
Senior Vice President, Value and Access
Vice President, Communications and Patient Advocacy
Senior Vice President, CFO, Ipsen North America
Vice President, Business Operations & Chief of Staff, North America
Senior Vice President, North America Medical Affairs
Vice President, Regulatory Affairs, Quality & Safety, North America